Showing results (11-20 of 116) with videos related to
Sort By:
Pageof 12
Lung Cancer (Amsterdam, Netherlands)|June 1, 2005
Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North AmericaCheryl Ho, Nevin Murray, Janessa Laskin, et al.American Journal of Clinical Oncology|November 1, 2012
Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC)Amanda Jagdis, Janessa Laskin, Desiree Hao, et al.American Journal of Clinical Oncology|June 1, 2014
Asian Versus Non-Asian Outcomes in Nasopharyngeal Carcinoma: A North American Population-based AnalysisSarah N Hamilton, Cheryl Ho, Janessa Laskin, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based reviewCheryl Ho, Katherine Ramsden, Yongliang Zhai, et al.Lung Cancer (Amsterdam, Netherlands)|December 3, 2014
Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohortKrista Noonan, King Mong Tong, Janessa Laskin, et al.The American Journal of Surgical Pathology|November 26, 2010
Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samplesJefferson Terry, Samuel Leung, Janessa Laskin, et al.Current Oncology (Toronto, Ont.)|August 25, 2023
Real-World Clinical Outcomes for Patients with <i>EGFR</i> and <i>HER2</i> Exon 20 Insertion-Mutated Non-Small-Cell Lung CancerKelly Li, Ian Bosdet, Stephen Yip, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 1, 2012
Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependentChris M J Conklin, Kenneth J Craddock, Cherry Have, et al.Lung Cancer (Amsterdam, Netherlands)|March 7, 2024
Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trialJ Connor Wells, Monica M Mullin, Cheryl Ho, et al.Breast Cancer Research and Treatment|October 21, 2019
Emotional distress and psychosocial needs in patients with breast cancer in British Columbia: younger versus older adultsHiten Naik, Bonnie Leung, Janessa Laskin, et al.Pageof 12